Active investment in new fields and research and development

「Total R&D expenses for the current interim consolidated accounting period were ¥7,009 million.」

「国内外グループ各社が参加する『グローバルサステナビリティミーティング』を開催し、重要課題の共有と取り組みを推進」

「Total R&D expenses for the fiscal year were ¥13,861 million, after eliminating intersegment transactions,」

「Total R&D expense for the interim consolidated accounting period was ¥6,741 million.」

「Total R&D expense for the six-month interim consolidated accounting period was ¥8,143 million.」

「Total R&D expenses for the fiscal year were ¥13,461 million, after eliminating intersegment transactions,」

「Total R&D expense for the nine-month period ended the current third quarter was ¥8,420 million.」

「Total R&D expense for the six-month period ended the current second quarter was ¥5,663 million.」

「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥2,507 million.」

「Total R&D expenses for the fiscal year were ¥11,115 million, after eliminating intersegment transactions,」

「Total R&D expense for the six-month period ended the current second quarter was ¥5,376 million.」

「Total R&D expense for the three-month period ended the current first quarter was ¥2,250 million.」

「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥6,222 million.」

「Total R&D expense for the six-month period ended the current second quarter was ¥4,283 million.」

「Total R&D expense for the three-month period ended the current first quarter was ¥1,894 million.」

「Segment profit, on an operating profit basis, declined 8.6% year on year to ¥10,485 million. Although the company worked to use selling, general and administrative expenses efficiently, the decline in revenue and increased R&D expenses for prescription drug development resulted in lower profit.」

「In terms of profit, upfront investment in new fields and restructuring costs increased, resulting in operating profit of ¥10,393 million (down 3.0% year on year), ordinary profit of ¥10,883 million (down 1.8%), and profit attributable to owners of the parent of ¥7,305 million (down 0.2%).」

「In terms of profit, upfront investment in new fields and restructuring costs increased, resulting in operating profit of ¥3,860 million (down 23.7% year on year), ordinary profit of ¥3,924 million (down 25.8%), and profit attributable to owners of the parent of ¥2,217 million (down 35.5%).」

「In terms of profit, although upfront investment in new fields continued, operating profit rose 47.4% year on year to ¥5,061 million, as revenue performed well and the company worked to use selling, general and administrative expenses efficiently.」

「In terms of profit, although upfront investment in new fields continued, strong sales and efforts to use selling, general and administrative expenses efficiently resulted in operating profit of ¥15,607 million (up 25.9% year on year), ordinary profit of ¥15,753 million (up 21.5%), and profit attributable to owners of the parent of ¥10,102 million (up 20.1%).」

「In terms of profit, although upfront investment in new fields continued, strong sales and efforts to use selling, general and administrative expenses efficiently resulted in operating profit of ¥8,655 million (up 33.9% year on year), ordinary profit of ¥8,754 million (up 28.3%), and profit attributable to owners of the parent of ¥5,647 million (up 34.8%).」

「In terms of profit, although upfront investment in new fields continued, strong sales and efforts to use selling, general and administrative expenses efficiently resulted in operating profit of ¥3,433 million (up 54.9% year on year), ordinary profit of ¥3,598 million (up 48.0%), and profit attributable to owners of the parent of ¥2,275 million (up 65.7%).」

「In terms of profit, although the company worked to use selling, general and administrative expenses efficiently, the continued upfront investment in new fields contributed to operating profit of ¥15,451 million, down 1.5% year on year.」

「In terms of earnings, although revenue declined and upfront investment in new fields continued, efforts to use selling, general and administrative expenses efficiently resulted in operating income of ¥12.392 billion, up 4.5% year on year; ordinary income of ¥12.966 billion, up 6.1%; and net income attributable to owners of the parent of ¥8.414 billion, up 7.8%.」

「In terms of profit, in addition to lower revenue, the continued upfront investment in new fields resulted in operating profit of ¥6,465 million, down 9.9% year on year, ordinary profit of ¥6,822 million, down 9.1%, and net profit attributable to owners of the parent of ¥4,191 million, down 14.0%.」

「Total R&D expenses for the cumulative first quarter were ¥1,334 million.」

「Although the business environment remains challenging, we intend to actively invest in new fields and research and development that will support future growth, and will continue working to help create the healthy society that Rohto Pharmaceutical seeks to achieve.」